Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $772

Benzinga Newsdesk www.benzinga.com Positive 85.5%

Neg 0% Neu 0% Pos 85.5%

Truist Securities analyst Gregory Renza maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $769 to $772.